In the summer of 2019, larotrectinib was approved as the first drug in Europe to be used in numerous different solid tumours if the tumour tissue displays a so-called NTRK gene fusion. Since such a fusion of a neurotrophic ...
Jan 16, 2020
0
1
(HealthDay)—For patients with chronic lymphocytic leukemia (CLL) in routine care, overall survival improved from 1995 to 2017, according to a study recently published in Leukemia & Lymphoma.
Dec 26, 2019
0
6
(HealthDay)—For relapsed or refractory acute myeloid leukemia (AML) with mutations in the FMS-like tyrosine kinase 3 gene (FLT3), treatment with a selective FLT3 inhibitor, gilteritinib, results in significantly longer ...
Oct 31, 2019
0
2
Among patients with multiple myeloma, African Americans and Hispanics start treatment with a novel therapy significantly later than white patients, according to a new study published today in Blood Advances. The study found ...
Oct 17, 2019
0
1
First-line osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non-small cell lung cancer (NSCLC), according to late breaking results ...
Sep 28, 2019
0
6
(HealthDay)—Many older patients with acute myeloid leukemia (AML) do not receive any active treatment, and they have worse survival than those receiving active treatment, according to a study published online Sept. 4 in ...
Sep 18, 2019
0
1
Patients with Stage IV squamous non-small cell lung cancer enrolled in clinical trial to test the immunotherapy atezolizumab and chemotherapy against chemotherapy alone experienced a longer survival rate, among a subgroup ...
Sep 10, 2019
0
0
Adding immunotherapy in the form of durvalumab to chemotherapy improves overall survival in patients with extensive-stage small cell lung cancer, according to research presented today at the IASLC 2019 World Conference on ...
Sep 9, 2019
0
0
Immunotherapeutic drugs are a potent way of transforming the immune system into a ferocious guard dog that can sniff out and destroy tumor cells. But for some therapies, it helps to have a leash. Without one, immunotherapies ...
Aug 14, 2019
0
94
(HealthDay)—A substantial proportion of older patients with high-risk acute myeloid leukemia (AML) treated with chemotherapy are long-term survivors, according to research published online June 7 in Cancer Medicine.
Jun 20, 2019
0
0
